EP3515420B1 - Pharmaceutical compositions for use in the therapy of blepharitis - Google Patents
Pharmaceutical compositions for use in the therapy of blepharitis Download PDFInfo
- Publication number
- EP3515420B1 EP3515420B1 EP17768468.5A EP17768468A EP3515420B1 EP 3515420 B1 EP3515420 B1 EP 3515420B1 EP 17768468 A EP17768468 A EP 17768468A EP 3515420 B1 EP3515420 B1 EP 3515420B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- anterior
- blepharitis
- posterior blepharitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010217 blepharitis Diseases 0.000 title claims description 106
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 61
- 238000002560 therapeutic procedure Methods 0.000 title claims description 29
- 238000011282 treatment Methods 0.000 claims description 43
- 230000002265 prevention Effects 0.000 claims description 30
- 208000024891 symptom Diseases 0.000 claims description 28
- 210000000744 eyelid Anatomy 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 9
- 210000000720 eyelash Anatomy 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 7
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 6
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 201000004700 rosacea Diseases 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims description 4
- 208000023715 Ocular surface disease Diseases 0.000 claims description 4
- 241001303601 Rosacea Species 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 238000010186 staining Methods 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 241000238876 Acari Species 0.000 claims description 2
- 206010061217 Infestation Diseases 0.000 claims description 2
- 241001674048 Phthiraptera Species 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 description 36
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 210000004175 meibomian gland Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 241001608562 Chalazion Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010044604 Trichiasis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- WRYIIOKOQSICTB-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane Chemical compound CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F WRYIIOKOQSICTB-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000000882 contact lens solution Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Blepharitis refers to a family of inflammatory disease processes of the eyelid(s). It usually involves the part of the eyelid where the eyelashes grow and affects both eyelids. A number of diseases and conditions can lead to blepharitis, such as bacterial infection, allergies, clogged oil glands or other conditions. The severity can vary and onset can be acute, resolving without treatment within 2 to 4 weeks, but more generally blepharitis is a long-standing chronic inflammation of varying severity.
- Anterior blepharitis can be divided anatomically into two sub-indications: Anterior and posterior blepharitis.
- Anterior blepharitis refers to inflammation mainly centered around the skin, eyelashes and follicles, while the posterior variant involves the meibomian gland orifices, meibomian glands, and tarsal plate.
- Anterior blepharitis usually is subdivided further into staphylococcal and seborrheic variants. Frequently, a considerable overlap exists in these processes in individual patients.
- Blepharitis often is associated with systemic diseases, such as rosacea, atopy and seborrheic dermatitis, as well as ocular diseases, such as dry eye syndromes, chalazion, trichiasis, conjunctivitis, and keratitis.
- systemic diseases such as rosacea, atopy and seborrheic dermatitis
- ocular diseases such as dry eye syndromes, chalazion, trichiasis, conjunctivitis, and keratitis.
- blepharitis frequently involves bacterial colonization of the eyelids. This results in direct microbial invasion of tissues, immune system-mediated damage, or damage caused by the production of bacterial toxins, waste products, and enzymes. Colonization of the lid margin is increased in the presence of seborrheic dermatitis or meibomian gland dysfunction. Patients with blepharitis typically present with symptoms of eye irritation, itching, erythema of the lids, and/or changes in the eyelashes.
- Blepharitis is often a chronic condition that is difficult to treat.
- a systematic and long-term commitment to a program of eyelid margin hygiene usually is the basis for the treatment of blepharitis, which is not a cure but a process to be carried out over prolonged periods of time.
- Useful medications in the treatment of blepharitis may include medications to fight infection (e.g. by topical antibiotics), to control inflammation (e.g. by topical corticosteroids), to affect the immune system (e.g. by immune suppressants) or by treating the underlying condition.
- conjunctivitis and keratitis can result as a complication of blepharitis and require additional treatment.
- the present invention relates to a pharmaceutical composition essentially consisting of 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis or symptoms associated therewith.
- the present invention provides a pharmaceutical composition consisting of 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of posterior blepharitis or symptoms associated therewith.
- the present invention provides a pharmaceutical kit for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis or symptoms associated therewith, comprising
- the present invention relates to a pharmaceutical composition essentially consisting of 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis or symptoms associated therewith.
- the present invention provides a pharmaceutical composition consisting of 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of posterior blepharitis or symptoms associated therewith.
- the clinical condition to be treated in a patient diagnosed therewith or to be prevented by therapy may be either anterior or posterior blepharitis, which are specific sub-indications of blepharitis as the more general indication.
- the anterior or posterior blepharitis to be treated according to the present invention may be acute or chronic and may or may not yet be manifested in the case of the prevention of a suspected anterior or posterior blepharitis.
- treatment means, as used herein, in a broad sense any act performed on a patient useful in the management or prevention of a medical condition or disease of such patient.
- anterior blepharitis refers to an inflammation mainly centered around the skin, eyelashes, and follicles of an eye or both eyes of a patient mainly affecting the outside front of the eyelid where eyelashes are attached.
- Anterior blepharitis as used herein further may be subdivided into staphylococcal and seborrheic variants. However, a considerable overlap may exist with respect to the named variants and processes in individual patients frequently.
- posterior blepharitis refers to a variant or subindication of blepharitis that involves the meibomian gland orifices, the meibomian glands, and the tarsal plate.
- Posterior blepharitis affects the inner edge of the eyelid that touches the eyeball. Frequently, it is linked to dysfunction of meibomian glands within the eyelids that secrete oils to help lubricate the eye, which creates a favorable environment for bacterial growth. Posterior blepharitis can also develop as a result of other skin conditions, such as acne rosacea and scalp dandruf.
- Both variants of blepharitis as referred to herein may or may not be associated with systemic diseases, such as, for example, rosacea, atopy, and seborrheic dermatitis, as well as ocular diseases, such as, for example, dry eye syndromes, chalazion, trichiasis, conjunctivitis, and keratitis.
- systemic diseases such as, for example, rosacea, atopy, and seborrheic dermatitis
- ocular diseases such as, for example, dry eye syndromes, chalazion, trichiasis, conjunctivitis, and keratitis.
- anterior or posterior blepharitis as referred to herein may or may not involve bacterial colonization of the eyelids and, as a result thereof, may involve direct microbial invasion of tissues, immune system-mediated damage, or damage caused by the production of bacterial toxins, waste products, and enzymes. Furthermore, colonization of the lid margin associated with anterior or posterior blepharitis as referred to herein may or may not be increased in the presence of seborrheic dermatitis or meibomian gland dysfunction. Furthermore, anterior or posterior blepharitis as referred to herein may typically occur together with symptoms of eye irritation, such as, for example, itching, erythema of the lids, and/or changes in the eyelashes.
- the present invention relates to a pharmaceutical composition for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis or symptoms associated therewith, wherein the anterior or posterior blepharitis is a posterior blepharitis. Accordingly, the present invention relates to a pharmaceutical composition for use in the therapy, treatment, prevention or amelioration of posterior blepharitis or symptoms associated therewith.
- the present invention relates to a pharmaceutical composition for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis or symptoms associated therewith, preferably posterior blepharitis, which may occur at certain levels of intensity.
- anterior or posterior blepharitis according to the present invention may occur with weak or light intensity or with an average intensity or with a severe intensity (i.e. an intensity above the average intensity) when compared with the distribution of intensities occurring in a group with a representative number of cases of blepharitis.
- the present invention relates to a pharmaceutical composition for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis or symptoms associated therewith, wherein the anterior or posterior blepharitis is a severe anterior or posterior blepharitis.
- the present invention relates to a pharmaceutical composition for use in the therapy, treatment, prevention or amelioration of severe posterior blepharitis, that means posterior blepharitis with severe intensity, or symptoms associated therewith.
- the pharmaceutical composition for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis, or symptoms associated therewith essentially consists of 1-perfluorohexyl-octane.
- 1-perfluorohexyl-octane is also known as F6H8, according to the nomenclature FnHm, wherein n is an integer representing the number of carbon atoms of the linear, unbranched perfluorinated segment and m is an integer representing the number of carbon atoms of the linear, unbranched hydrocarbon segment.
- the pharmaceutical composition for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis consists of 1-perfluorohexyl-octane.
- the pharmaceutical compositions for use according to the present invention may, as an alternative, be referred to as "pharmaceutical preparation” or "medicinal product”.
- the pharmaceutical composition for use according to the present invention is usually provided as a clear solution, preferably in sterilized form.
- the pharmaceutical compositions for use according to the present invention are substantially free of a dissolved pharmacological active ingredient which is not 1-perfluorohexyl-octane.
- pharmacological active ingredient refers to any type of pharmaceutically active compound or drug, i.e. one that produces a pharmacological effect and that may accordingly be useful in the prevention, diagnosis, stabilization, treatment, or generally speaking, the management of a condition or disease.
- the pharmaceutical compounds for use according to the present invention have beneficial therapeutic effects in the treatment or prevention of anterior or posterior blepharitis.
- the pharmaceutical compositions for use according to the present invention are substantially free of water and/or substantially free of a preservative.
- the term 'substantially free' in reference to a composition constituent refers to the presence of said constituent in no more than trace amounts and that if present in trace amounts the constituent provides no technical contribution to the composition.
- compositions for use according to the present invention are commercially available and may be purchased under the tradename NovaTears ® (Novaliq GmbH, Germany) or EvoTears ® (URSAPHARM Arzneiffen GmbH, Germany).
- the pharmaceutical composition for use according to the present invention may be topically administered to a surface of the eye, into a lower eyelid, to the lacrimal sac or to an ophthalmic tissue of a patient in need thereof.
- single droplets of the pharmaceutical composition preferably single droplets of NovaTears ®
- the droplets may be administered into a pocket of the eyelid that may be formed by gently pulling down the lower eyelid of an eye.
- the droplets of the pharmaceutical composition especially the droplets of the pharmaceutical composition consisting essentially of 1-perfluorohexyl-octane usually have a volume of about 8 to 15 ⁇ L, often a volume of about 10 ⁇ l per droplet.
- the present pharmaceutical compositions are administered in an amount of 1 to 6 droplets, preferably 3 to 4 droplets to each eye per day corresponding to a daily overall volume of the pharmaceutical composition of 30 to 40 ⁇ l per eye.
- the pharmaceutical is administered at a dose of 1 droplet per eye per administration with 3 to 4 administrations per day.
- modes and volumes of administration as well as the duration of the treatment can vary significantly.
- the anterior or posterior blepharitis may be associated with an underlying clinical condition selected from the group consisting of bacterial infections, seborrheic dermatitis, clogged or malfunctioning oil glands in the eyelids, rosacea, allergic reactions and infestation with eyelash mites and/or lice. Allergic reactions may be caused by or attributed to for example, eye medications, to contact lens solutions or to certain eye makeup.
- the pharmaceutical composition for use according to the present invention is associated with mybomian gland dysfunction and/or dry eye disease (DED).
- DED dry eye disease
- the pharmaceutical composition for use according to the present invention is not administered to patients wearing contact lenses.
- the pharmaceutical composition for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis, or symptoms associated therewith is administered to a patient having a Tear Film Break-Up Time (TFBUT; Shapiro A., et. al. Am J Ophthalmol. 1979 Oct; 88(4):752-7 ) of up to 10s, preferably of up to 6s. ( Shapiro A., et. al. Am J Ophthalmol. 1979 Oct; 88(4):752-7 ).
- TFBUT Tear Film Break-Up Time
- the pharmaceutical composition for use according to the present invention is administered to a patient having an Ocular Surface Disease Index in the range of from 16 to 55 ( Schiffman, R.M., et. al, Arch. Ophthalmol. 118:615-621, 2000 ).
- the pharmaceutical composition for use according to the present invention is administered to a patient having a Schirmer I Test value ( Shapiro A., et.al. Am J Ophthalmol. 1979 Oct;88(4):752-7 ) of at least 2mm (2mm and above), preferably 5mm and above as recorded during a 5 min test period.
- a Schirmer I Test value Shapiro A., et.al. Am J Ophthalmol. 1979 Oct;88(4):752-7 ) of at least 2mm (2mm and above), preferably 5mm and above as recorded during a 5 min test period.
- the pharmaceutical composition for use according to the present invention is administered to a patient having an added peripheral corneal and conjunctival Oxford staining grade of up to 10. ( Bron, A.J., et.al., Cornea. 22:640-650, 2003 .)
- the pharmaceutical composition for use according to the present invention is administered to a patient having a Tear Film Break-Up Time of up to 10s, an Ocular Surface Disease Index in the range of from 16 to 55, a Schirmer I Test value of at least 2mm, and an added peripheral corneal and conjunctival Oxford staining grade of up to 10.
- the present disclosure as described in detail above relates to a method of treating a patient suffering from anterior or posterior blepharitis or symptoms associated therewith, comprising topically administering a pharmaceutical composition comprising or essentially consisting of 1-perfluorohexyl-octane to the eye of that patient.
- the method comprises topically administering a pharmaceutical composition consisting of 1-perfluorohexyl-octane to the eye of that patient.
- the treatment of posterior blepharitis is preferred according to all embodiments outlined above for the first aspect of the invention.
- the present invention relates to a pharmaceutical kit for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis or symptoms associated therewith, comprising
- the pharmaceutical kit comprises a pharmaceutical composition for use as described above for the first aspect of the present invention.
- the pharmaceutical composition is a pharmaceutical composition for use according to the first aspect of the invention consisting of 1-perfluorohexyl-octane.
- a container as used in connection with item b) of this aspect of the invention can be provided in any suitable form as a container for single use holding a single dose of the pharmaceutical composition or as a container for multiple uses holding a plurality of single doses.
- the container comprises a dispensing means which allows for dropwise topical administration of the pharmaceutical composition to a surface of the eye of a patient.
- the container comprising a dispensing means may be a conventional dropper bottle such as a bottle made of glass or a thermoplastic elastomer with a suitable dispensing means or single-use droppers.
- the dispensing means comprises a dropper of dimensions such as to dispense droplets having a volume of about 8 to 15 ⁇ L, preferably of about 10 ⁇ l. With a small droplet volume, precise dosing to the eye can be achieved and an excess amount of discharge of a substantial fraction of the composition from the eye subsequent to administration can be avoided.
- Directions for use of the pharmaceutical composition according to item c) of this aspect of the invention can be provided in any suitable form such as, for example, as an enclosed label or instruction leaflet in printed or other readable form.
- the directions for use can be provided in electronic or computer readable form, such as a barcode or a OR-code.
- F6H8 1-perfluorohexyloctane
- Said formulation consists essentially of 1-perfluorohexyloctane (F6H8), it is water-free and contains no additional preservatives or ingredients.
- a dose of 3 to 4 droplets (corresponding to 30 to 40 ⁇ l, 10 ⁇ l per drop) per eye and day were administered topically to the eye, with 1 droplet being administered as a single dose.
- NovaTears ® single droplets were administered directly to the surface of the eye into a pocket that was formed by gently pulling down the lower eyelid. Assessment of the eyes treated was performed once before the start of NovaTears ® administration (baseline) and once after 7 weeks of treatment (follow-up).
- Anterior blepharitis involves inflammation of the lid margin anterior to the gray line and is usually concentrated around the eyelashes and follicles.
- Posterior blepharitis involves inflammation of the posterior lid margin. The severity of anterior and posterior blepharitis was rated separately for each eye by selecting one of the following ratings: “none”, “+”, “++”, “+++” (with "+++” indicating most severe blepharitis anterior or posterior).
- Table I summarizes the assessment of 122 eyes from 61 patients, with the results of right and left eyes combined.
- the evaluation of anterior blepharitis showed that patients clearly profit from the treatment with 1-perfluorohexyloctane (F6H8).
- the severity of blepharitis was observed to be decreased for all patients, including patients with blepharitis severity scores indicated as "++" and "+”.
- Table I Assessment of anterior blepharitis Grade none + ++ +++ Baseline 48 59 15 0
- Table II summarizes the assessment of 122 eyes from 61 patients, with the results of right and left eyes combined.
- the assessment of posterior blepharitis showed that the severity of blepharitis was observed to be decreased for all patients after treatment with 1-perfluorohexyloctane, including patients with blepharitis severity scores rated as "++" and "+".
- Table II Assessment of posterior blepharitis Grade none + ++ +++ Baseline 31 53 32 6
- Table III Assessment of anterior blepharitis (sum scores of severity ratings), changes from baseline for both eyes - shift table follows-up Baseline none + ++ +++ none 31 15 2 0 + 38 20 1 0 ++ 4 7 4 0 +++ 0 0 0 0 0
- Table IV Assessment of posterior blepharitis (sum scores of severity ratings), changes from baseline for both eyes - shift table follows-up Baseline 0 (none) + ++ +++ 0 (none) 26 5 0 0 + 20 30 3 0 ++ 10 14 8 0 +++ 4 2 0 0
- lid margin assessment revealed that all abnormal lid margin features such as teleangiectasia, plugging and lid swelling were significantly reduced after treatment with 1-perfluorohexyloctane (F6H8).
- Table V Assessment of lid margin Teleangiectasia Plugging Lid Swelling Baseline 74 90 30 Follow-up 49 59 20
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16190138 | 2016-09-22 | ||
| PCT/EP2017/073697 WO2018054932A1 (en) | 2016-09-22 | 2017-09-20 | Pharmaceutical compositions for use in the therapy of blepharitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3515420A1 EP3515420A1 (en) | 2019-07-31 |
| EP3515420B1 true EP3515420B1 (en) | 2023-11-08 |
| EP3515420C0 EP3515420C0 (en) | 2023-11-08 |
Family
ID=56990295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17768468.5A Active EP3515420B1 (en) | 2016-09-22 | 2017-09-20 | Pharmaceutical compositions for use in the therapy of blepharitis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11684589B2 (zh) |
| EP (1) | EP3515420B1 (zh) |
| JP (1) | JP7012075B2 (zh) |
| KR (1) | KR102614858B1 (zh) |
| CN (2) | CN109890374A (zh) |
| AU (1) | AU2017329772B2 (zh) |
| CA (1) | CA3036297C (zh) |
| ES (1) | ES2969758T3 (zh) |
| MX (1) | MX2019003363A (zh) |
| PL (1) | PL3515420T3 (zh) |
| WO (1) | WO2018054932A1 (zh) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| PL3181119T3 (pl) | 2012-09-12 | 2020-01-31 | Novaliq Gmbh | Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki |
| CN113679698B (zh) | 2012-09-12 | 2022-07-26 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| AU2014295052B2 (en) | 2013-07-23 | 2018-08-30 | Novaliq Gmbh | Stabilized antibody compositions |
| CN111743882A (zh) | 2015-09-30 | 2020-10-09 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| ES2803248T3 (es) | 2015-09-30 | 2021-01-25 | Novaliq Gmbh | 2-perfluorohexil octano para administración oftálmica |
| ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
| CA3036306C (en) | 2016-09-23 | 2024-05-14 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| CN110678207B (zh) | 2017-04-21 | 2024-08-02 | 德马利克治疗公司 | 碘组合物 |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| CN111372566A (zh) | 2017-09-27 | 2020-07-03 | 诺瓦利克有限责任公司 | 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物 |
| WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| WO2019166631A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| CA3111873A1 (en) * | 2018-09-22 | 2020-03-26 | Novaliq Gmbh | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
| WO2020074697A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
| US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
| US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
| JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
| US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
| US5370313A (en) | 1994-01-10 | 1994-12-06 | Beard; Walter C. | Sterile liquid dispenser |
| DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
| FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| IN184589B (zh) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
| US6335335B2 (en) | 1997-11-05 | 2002-01-01 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
| US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| PT983037E (pt) | 1998-02-09 | 2003-09-30 | Macrochem Corp | Verniz para unhas antifungico |
| DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| CN1221249C (zh) | 1998-08-19 | 2005-10-05 | 斯凯伊药品加拿大公司 | 普鲁泊福的可注射水分散体 |
| US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| PT1666026E (pt) | 1999-02-08 | 2012-03-15 | Intarcia Therapeutics Inc | Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos |
| EP1124416A1 (en) | 1999-03-15 | 2001-08-22 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
| US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| DE10024413A1 (de) | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| WO2002089849A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
| WO2003020250A1 (en) | 2001-09-04 | 2003-03-13 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Plaster for the treatment of dysfunctions and disorders of nail growth |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
| MXPA06002163A (es) | 2003-08-25 | 2006-05-22 | Foamix Ltd | Espuma farmaceutica de penetracion. |
| US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
| ES2377932T3 (es) | 2003-10-10 | 2012-04-03 | Ferring Bv | Formulación farmacéutica transdérmica para minimizar los residuos sobre la piel |
| WO2005051305A2 (en) | 2003-11-19 | 2005-06-09 | Barnes-Jewish Hospital | Enhanced drug delivery |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| ES2387619T3 (es) | 2004-04-19 | 2012-09-27 | Centre National De La Recherche Scientifique (Cnrs) | Suplementos de tensioactivos pulmonares |
| US20050288197A1 (en) | 2004-06-08 | 2005-12-29 | Ocularis Pharma, Inc. | Silicone polymer topical eye compositions and methods of use |
| US7063241B2 (en) | 2004-06-10 | 2006-06-20 | Allergan, Inc. | Dispensing tip |
| MX2007000208A (es) | 2004-07-01 | 2007-08-07 | Schepens Eye Res Inst | Composiciones y metodos para tratar trastornos y condiciones del ojo. |
| US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| EP1688161A1 (en) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
| GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
| EP1922060B1 (en) | 2005-08-05 | 2009-01-14 | Bharat Serums & Vaccines Ltd. | Intravenous propofol emulsion compositions having preservative efficacy |
| FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
| DE102005055811A1 (de) | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| BRPI0714587A2 (pt) | 2006-07-25 | 2013-05-07 | Osmotica Corp | suluÇço oftÁlmica aquosa e uso da nesna |
| US20080089923A1 (en) | 2006-09-29 | 2008-04-17 | Burkstrand Michael J | Biodegradable ocular implants and methods for treating ocular conditions |
| US8328775B2 (en) | 2006-12-07 | 2012-12-11 | Sun Pharma Advanced Research Company Limited | Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop |
| FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| JP2011515494A (ja) * | 2008-03-26 | 2011-05-19 | エリック ドネンフェルド， | テトラサイクリンファミリー抗生物質を用いる、眼瞼縁および涙液膜機能の改善ならびに眼瞼縁疾患の処置のための方法 |
| DK2110126T3 (da) | 2008-04-18 | 2012-02-27 | Novaliq Gmbh | Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område |
| US20100006600A1 (en) | 2008-07-14 | 2010-01-14 | Dascanio Gustavo A | Fluid dispenser including hydrophobic ring |
| WO2010062394A2 (en) | 2008-11-26 | 2010-06-03 | Surmodics, Inc. | Implantable ocular drug delivery device and methods |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| CN102802619A (zh) | 2009-06-25 | 2012-11-28 | 狮王株式会社 | 眼科用组合物 |
| JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
| BRPI1006790B8 (pt) | 2009-07-24 | 2021-05-25 | Mika Pharma Ges Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico |
| EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| TR201901309T4 (tr) | 2011-01-04 | 2019-02-21 | Novaliq Gmbh | Semiflorlanmış alkanları içeren o/w emülsiyonları. |
| WO2012160180A2 (en) | 2011-05-25 | 2012-11-29 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
| PT3192501T (pt) | 2011-05-25 | 2020-07-31 | Novaliq Gmbh | Composição farmacêutica tópica à base de alcanos semifluorados |
| BR112014017719A8 (pt) | 2012-01-23 | 2017-07-11 | Novaliq Gmbh | Composições de proteína estabilizada baseadas em alcanos semifluorados |
| US9549966B2 (en) | 2012-02-21 | 2017-01-24 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| US9878000B2 (en) | 2012-06-20 | 2018-01-30 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
| PL3181119T3 (pl) | 2012-09-12 | 2020-01-31 | Novaliq Gmbh | Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki |
| CN113679698B (zh) | 2012-09-12 | 2022-07-26 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| AU2014295052B2 (en) | 2013-07-23 | 2018-08-30 | Novaliq Gmbh | Stabilized antibody compositions |
| MX2016012684A (es) | 2014-03-31 | 2017-05-01 | Amcor Ltd | Recipiente de liberacion controlada. |
| EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| EP3179975A4 (en) | 2014-08-13 | 2018-04-18 | University of Florida Research Foundation, Inc. | Preservative removal from eye drops |
| ES2803248T3 (es) | 2015-09-30 | 2021-01-25 | Novaliq Gmbh | 2-perfluorohexil octano para administración oftálmica |
| CN111743882A (zh) | 2015-09-30 | 2020-10-09 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| KR20190003997A (ko) | 2016-06-01 | 2019-01-10 | 해롤드 리차드 헬스트롬 | 부교감 신경제와 항교감 신경제를 이용한 안구 건조증의 치료 |
| ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
| CA3036306C (en) | 2016-09-23 | 2024-05-14 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| KR20190060787A (ko) | 2016-09-28 | 2019-06-03 | 노바리크 게엠베하 | 카나비노이드 수용체 결합 리간드를 포함하는 조성물 |
| EP3558308A1 (en) | 2016-12-22 | 2019-10-30 | Novaliq GmbH | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| CN110267645A (zh) | 2016-12-23 | 2019-09-20 | 诺瓦利克有限责任公司 | 用于治疗干眼病的眼用组合物 |
| CN110678207B (zh) | 2017-04-21 | 2024-08-02 | 德马利克治疗公司 | 碘组合物 |
| EP3618782B1 (en) | 2017-05-06 | 2021-05-26 | Novaliq GmbH | Drop dispenser |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| CN111372566A (zh) | 2017-09-27 | 2020-07-03 | 诺瓦利克有限责任公司 | 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物 |
| WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| WO2019166631A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| CN111867560B (zh) | 2018-03-28 | 2024-08-13 | 诺瓦利克有限责任公司 | 包含噻吗洛尔的药物组合物 |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| CA3111873A1 (en) | 2018-09-22 | 2020-03-26 | Novaliq Gmbh | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
| WO2020074697A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CA3117594A1 (en) | 2018-11-27 | 2020-06-04 | Novaliq Gmbh | Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters |
| WO2020152046A1 (en) | 2019-01-21 | 2020-07-30 | Novaliq Gmbh | Pharmaceutical composition for the treatment of ocular neovascularisation |
| WO2020239646A1 (en) | 2019-05-24 | 2020-12-03 | Novaliq Gmbh | Ophthalmic composition for the treatment of ocular allergy |
-
2017
- 2017-09-20 ES ES17768468T patent/ES2969758T3/es active Active
- 2017-09-20 WO PCT/EP2017/073697 patent/WO2018054932A1/en unknown
- 2017-09-20 AU AU2017329772A patent/AU2017329772B2/en active Active
- 2017-09-20 JP JP2019515654A patent/JP7012075B2/ja active Active
- 2017-09-20 EP EP17768468.5A patent/EP3515420B1/en active Active
- 2017-09-20 CN CN201780058495.5A patent/CN109890374A/zh active Pending
- 2017-09-20 CN CN202310020159.9A patent/CN116172987A/zh active Pending
- 2017-09-20 KR KR1020197009962A patent/KR102614858B1/ko active IP Right Grant
- 2017-09-20 PL PL17768468.5T patent/PL3515420T3/pl unknown
- 2017-09-20 MX MX2019003363A patent/MX2019003363A/es unknown
- 2017-09-20 CA CA3036297A patent/CA3036297C/en active Active
- 2017-09-20 US US16/336,018 patent/US11684589B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190057324A (ko) | 2019-05-28 |
| CN116172987A (zh) | 2023-05-30 |
| JP7012075B2 (ja) | 2022-01-27 |
| CA3036297A1 (en) | 2018-03-29 |
| CN109890374A (zh) | 2019-06-14 |
| KR102614858B1 (ko) | 2023-12-18 |
| AU2017329772B2 (en) | 2023-02-02 |
| US11684589B2 (en) | 2023-06-27 |
| US20190274970A1 (en) | 2019-09-12 |
| WO2018054932A1 (en) | 2018-03-29 |
| MX2019003363A (es) | 2019-10-02 |
| CA3036297C (en) | 2023-09-05 |
| JP2019532931A (ja) | 2019-11-14 |
| EP3515420C0 (en) | 2023-11-08 |
| EP3515420A1 (en) | 2019-07-31 |
| PL3515420T3 (pl) | 2024-04-08 |
| AU2017329772A1 (en) | 2019-04-04 |
| ES2969758T3 (es) | 2024-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3515420B1 (en) | Pharmaceutical compositions for use in the therapy of blepharitis | |
| Aguayo Bonniard et al. | Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK) | |
| US20240245625A1 (en) | Opthalmic compositions comprising f6h8 | |
| US10780071B2 (en) | Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders | |
| CN111568906B (zh) | 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的配制品 | |
| Donnenfeld et al. | Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery | |
| Bagnis et al. | Antiglaucoma drugs: The role of preservative-free formulations | |
| JPWO2018074421A1 (ja) | 眼科用剤及び眼科用薬 | |
| EP3576799A1 (en) | Ophthalmic compositions for therapeutic and prophylactic uses | |
| Rahman et al. | Recurrence rate of pterygium following surgical excision with intraoperative versus postoperative mitomycin-C | |
| Hakim et al. | Medical management of blepharitis | |
| US20230414573A1 (en) | Synergistic ophthalmological composition in a low-concentration dose that is effective in the prevention, control and eradication of presbyopia | |
| TW202033186A (zh) | 眼科用組成物 | |
| Hom | Investigational agent aims to eradicate Demodex mites | |
| Morgenstern | TREAT CORNEAL ECTASIA WITH CROSSLINKING. | |
| Noecker et al. | BAK in Topical Eyedrops: Should You Be Concerned? | |
| McNeil | Effective management of dry eye and ocular surface disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20190423 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20210115 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/00 20060101ALI20230508BHEP Ipc: A61K 9/08 20060101ALI20230508BHEP Ipc: A61P 29/00 20060101ALI20230508BHEP Ipc: A61P 27/02 20060101ALI20230508BHEP Ipc: A61K 31/02 20060101AFI20230508BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20230524 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017076309 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| U01 | Request for unitary effect filed |
Effective date: 20231110 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20231116 |
|
| U1N | Appointed representative for the unitary patent procedure changed [after the registration of the unitary effect] |
Representative=s name: PHARMA PATENTS INTERNATIONAL AG; CH |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240209 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240308 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240308 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240209 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2969758 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240522 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231108 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240208 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231108 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231108 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231108 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231108 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231108 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017076309 Country of ref document: DE |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240927 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240920 Year of fee payment: 8 |
|
| 26N | No opposition filed |
Effective date: 20240809 |